News for Agenus Inc. (AGEN)

**media[552077]**

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of c

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting in Los A

**media[548588]**

Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST (instead of Tuesd

Here is how Agenus (AGEN) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Associatio

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Here is how Agenus (AGEN) and Concentra Group (CON) have performed compared to their sector so far this year.

**media[522870]**

Agenus reports promising colorectal cancer treatment data

Agenus (AGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Agenus (AGEN) and Abbott (ABT) have performed compared to their sector so far this year.

Agenus Inc. (AGEN) experienced a notable stock price increase of 5.07%, reaching $2.90 per share. The trading volume was 257,797 shares with a turnover rate of

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its fina

Agenus Inc. (AGEN), a biotechnology company, saw its stock price plummet by 5.50%, trading at $3.53 per share with a trading volume of 480,929 shares. The compa

Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer.

Agenus Inc. (”œAgenus” or the ”œCompany”) (Nasdaq: AGEN), an immuno-oncology company focused on innovationhas successfully secured a $22 million non-amor